Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,575 stopped studies mapped to Malignant Breast Neoplasm and descendants · 90% state a reason
Over the 1,575 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05176080 | Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive,… | Phase 1 / Phase 2 | terminated | Jan 4, 2022 | Henan Cancer Hospital | Investigators' decision | Other (stated, no rule matched) |
| NCT05555251 | BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid…(CONTRAST) | Phase 1 / Phase 2 | terminated | Sep 26, 2022 | BioInvent International AB | After the completion of phase IA, for business reasons it was decided to terminate the study. | Sponsor / business decision |
| NCT03549000 | A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in… | Phase 1 | terminated | Jun 7, 2018 | Novartis Pharmaceuticals | After review of data which showed low likelihood of efficacy in these patients Novartis decided to… | Safety / toxicity |
| NCT03623945 | Autoantibodies in Breast Cancer Detection(ABCD) | — | terminated | Aug 9, 2018 | Sanford Health | Study closed to enrollment and data and specimen collection due to lack of funding. | Enrollment / accrual |
| NCT03473691 | Pilot Study of Glembatumumab Vedotin Following Doxorubicin and Cytoxan as Neo-adjuvant…(Breast50) | Early Phase 1 | withdrawn | Mar 22, 2018 | University of Virginia | Pharmaceutical company decided to withdraw funding and not provide drug. | Funding |
| NCT02883361 | Motivational Enhancement Therapy to Improve Adherence to Aromatase Inhibitors(MI for AIs) | Phase 2 / Phase 3 | withdrawn | Aug 30, 2016 | University of Calgary | Our team decided to conduct more preliminary work on understanding AI adherence to support the… | Other (stated, no rule matched) |
| NCT04675827 | De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR…(Decrescendo) | Phase 2 | terminated | Dec 19, 2020 | Jules Bordet Institute | Serious concerns on the slow recruitment of the study that impacts the robustness of the scientific… | Enrollment / accrual |
| NCT05395936 | Mastectomy Flap Temperature Study | N/A | terminated | May 27, 2022 | Wake Forest University Health Sciences | low accruals | Enrollment / accrual |
| NCT04160182 | Feasibility and Effectiveness of an Internet-based Intervention to Manage Fatigue in… | N/A | withdrawn | Nov 12, 2019 | University of Toledo Health Science Campus | Due to COVID this trial never got up and running. | COVID-19 / pandemic |
| NCT04232319 | Feasibility and Effectiveness of a Sleep Hygiene Education Program for Sleep Issues in… | N/A | withdrawn | Jan 18, 2020 | University of Toledo Health Science Campus | Due to COVID this study was never started. | COVID-19 / pandemic |
| NCT04657679 | Pharmacokinetics and Pharmacogenomics of Ribociclib in Race-based Cohorts(LEANORA) | Phase 4 | terminated | Dec 8, 2020 | Georgetown University | Sufficient accrual into the African American/Black patient cohort and insufficient accrual into the… | Enrollment / accrual |
| NCT05427344 | Effectiveness of Aquatic Exercise on Fatigue, Neuropathy and Quality of Life Among Cancer… | N/A | withdrawn | Jun 22, 2022 | Tel Aviv University | The study was stopped because we were unable to recruit participants as planned. Therefore, it was… | Enrollment / accrual |
| NCT04985357 | Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor… | — | withdrawn | Aug 2, 2021 | Travera Inc | Abandoned prior to launch. | Other (stated, no rule matched) |
| NCT03514121 | FPA150 in Patients With Advanced Solid Tumors(FPA150-001) | Early Phase 1 | terminated | May 2, 2018 | Five Prime Therapeutics, Inc. | The Sponsor terminated the study for reasons unrelated to safety. | Safety / toxicity |
| NCT02317783 | Amyloid Plaque Deposition in Chemotherapy-Induced Cognitive Impairment | Phase 2 | terminated | Dec 16, 2014 | University of Utah | Enrollment challenges | Enrollment / accrual |
| NCT05457842 | A Study to Find the Best Dose of ASP5354 to Show Lymph Nodes in People With Breast Cancer… | Phase 2 | terminated | Jul 14, 2022 | Astellas Pharma Inc | Company's strategic decision | Sponsor / business decision |
| NCT01217411 | RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating… | Phase 1 / Phase 2 | terminated | Oct 8, 2010 | National Cancer Institute (NCI) | Other - Protocol moved to Administratively Complete | Other (stated, no rule matched) |
| NCT04007549 | Brief Intervention for Tobacco and Alcohol Risk Reduction for Couple During Breast Cancer…(IBMC) | N/A | withdrawn | Jul 5, 2019 | Institut Bergonié | Internal organisation reason | Other (stated, no rule matched) |
| NCT04060862 | A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib…(IPATunity150) | Phase 1 | terminated | Aug 19, 2019 | Hoffmann-La Roche | The decision to not open the Phase III portion was based on a strategic sponsor decision and not… | Safety / toxicity |
| NCT05592483 | An Observational Study of Patients Receiving T-DXd for Treatment of HER2+, and HER2-low…(DB RESPOND) | — | terminated | Oct 24, 2022 | AstraZeneca | The DESTINY-Breast RESPOND study was terminated early due to start-up delays and slow enrolment,… | Safety / toxicity |
| NCT05076591 | IMM2902, a HER2/SIRPα Bispecific MAb-Trap Antibody-receptor Fusion Protein, in Patients… | Phase 1 | suspended | Oct 13, 2021 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Due to a business decision resulting in the deprioritization of this project and with no safety… | Safety / toxicity |
| NCT05177796 | Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the… | Phase 2 | withdrawn | Jan 5, 2022 | M.D. Anderson Cancer Center | 0 participants recruited | Enrollment / accrual |
| NCT05488444 | A Feasibility and Acceptability Pilot Study Evaluating a Patient-Specific Targeted… | Phase 2 | withdrawn | Aug 4, 2022 | M.D. Anderson Cancer Center | 0 Participants Accrued | Enrollment / accrual |
| NCT03238053 | Laser Treatment of Genito-urinary Syndrome in Women | N/A | withdrawn | Aug 3, 2017 | Herning Hospital | Hospital terminated treatment with laser | Other (stated, no rule matched) |
| NCT03207867 | A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and… | Phase 2 | terminated | Jul 5, 2017 | Novartis Pharmaceuticals | Sponsor decision | Sponsor / business decision |
| NCT04899349 | Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in…(EPIK-B4) | Phase 2 | terminated | May 24, 2021 | Novartis Pharmaceuticals | Study was early terminated due to slow recruitment and emerging data showing that prophylactic use… | Safety / toxicity |
| NCT01127971 | Patient Registry: Partial Breast Irradiation(PBI Registry) | — | terminated | May 21, 2010 | Wake Forest University Health Sciences | administrative reasons (no impact/concern of subject rights, welfare, safety) | Safety / toxicity |
| NCT03872388 | Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who… | Phase 2 | terminated | Mar 13, 2019 | M.D. Anderson Cancer Center | Due to slow accrual | Enrollment / accrual |
| NCT05650086 | Novel Thermal Imaging Technique for Breast Screening | — | terminated | Dec 14, 2022 | University of Arizona | PI has left the institution (University of Arizona Cancer Center). | Other (stated, no rule matched) |
| NCT02681523 | ALERT: A Phase II Study of Alternating Eribulin and Hormonal Therapy in Pre-treated ER+ve…(ALERT) | Phase 2 | terminated | Feb 12, 2016 | Imperial College London | Slow patient recruitment | Enrollment / accrual |
| NCT03043794 | Study of Stereotactic Radiotherapy for Breast Cancer | Phase 2 | terminated | Feb 6, 2017 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | PI closed. Unable to enroll enough patients to collect and analyze data. | Enrollment / accrual |
| NCT05655598 | TAS-116 Plus Palbociclib in Breast and Rb-null Cancer | Phase 1 | withdrawn | Dec 19, 2022 | Brown University | Lack of accrual | Enrollment / accrual |
| NCT04950010 | High-intensity Exercise After Treatment(HEAT) | N/A | terminated | Jul 2, 2021 | University of Nebraska | Original PI moved to a new institution | Other (stated, no rule matched) |
| NCT05966584 | A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer | Phase 2 | terminated | Jul 28, 2023 | Memorial Sloan Kettering Cancer Center | Limited amount of eligible participants | Other (stated, no rule matched) |
| NCT04123704 | Sitravatinib in Metastatic Breast Cancer | Phase 2 | terminated | Oct 11, 2019 | Xiang Zhang | Terminated by sponsor due to lack of interest | Other (stated, no rule matched) |
| NCT04835597 | Precision Performance Status Assessment in Breast Cancer Patients Receiving Neoadjuvant… | — | terminated | Apr 8, 2021 | M.D. Anderson Cancer Center | IRB Study Closure | Other (stated, no rule matched) |
| NCT03674827 | Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC | Phase 1 | terminated | Sep 18, 2018 | Pfizer | The study was terminated due to the review of the asset (VBIR-2) within the Sponsor's oncology… | Safety / toxicity |
| NCT03498716 | A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant…(IMpassion030) | Phase 3 | terminated | Apr 17, 2018 | Hoffmann-La Roche | The study was terminated by the sponsor following interim analysis as the primary endpoint of iDFS… | Efficacy / futility |
| NCT04205786 | Vitamin B12 for Aromatase Inhibitors Associated Musculoskeletal Symptoms in Breast Cancer | N/A | withdrawn | Dec 19, 2019 | Case Comprehensive Cancer Center | Logistics requirements, research cancelled | Other (stated, no rule matched) |
| NCT04363892 | Combined Optical and Infrared Imaging for Early Prediction of Erythema During Breast and… | N/A | terminated | Apr 27, 2020 | Nova Scotia Health Authority | The PI resigned | Other (stated, no rule matched) |
| NCT02037529 | Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients… | Phase 3 | suspended | Jan 16, 2014 | Academic and Community Cancer Research United | Total enrollment number is being lowered | Enrollment / accrual |
| NCT04946864 | A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in… | Phase 1 / Phase 2 | suspended | Jul 1, 2021 | Ascentage Pharma Group Inc. | Company Decision | Sponsor / business decision |
| NCT06065059 | Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant… | Phase 1 / Phase 2 | terminated | Oct 3, 2023 | Tango Therapeutics, Inc. | Terminated due to safety | Safety / toxicity |
| NCT03387085 | QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed… | Phase 1 / Phase 2 | terminated | Dec 29, 2017 | ImmunityBio, Inc. | Study halted prematurely and will not resume; participants are no longer being examined or… | Other (stated, no rule matched) |
| NCT05156606 | Testosterone & Tamoxifen Trial(T&T) | N/A | terminated | Dec 14, 2021 | University Medical Center Groningen | Five patients were included; it did not succeed in recruiting the target number of 6 patients. This… | Enrollment / accrual |
| NCT05672342 | Phytocannabinoids for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy… | Early Phase 1 | withdrawn | Jan 5, 2023 | City of Hope Medical Center | withdrawn | Other (stated, no rule matched) |
| NCT04880369 | Phytoestrogens and Breast Cancer - Effects of Phytoestrogens on Markers of Disease…(DAGMAR) | N/A | withdrawn | May 10, 2021 | Danish Cancer Society | Disapproved by relevant Danish ethical committee | Other (stated, no rule matched) |
| NCT03127098 | QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803… | Phase 1 / Phase 2 | terminated | Apr 25, 2017 | NantCell, Inc. | The study was terminated before any dose escalation occurred in order to pursue other studies… | Other (stated, no rule matched) |
| NCT06126003 | Gut and Tumor Microbiome in Patients With Early Stage (II-III), Locally Advanced or… | — | terminated | Nov 13, 2023 | BioCorteX Inc | Did not reach enrollment goals | Enrollment / accrual |
| NCT04395339 | GM1 Prophylaxis for WBRT Related Cognitive Dysfunction(GLORY) | Phase 3 | terminated | May 20, 2020 | Sun Yat-sen University | Difficulty accruing subjects the study accrual was closed | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Dec 17, 2024source: clinicaltrials